Shares of REGENXBIO Inc. (NASDAQ:RGNX) saw unusually-strong trading volume on Friday . Approximately 801,458 shares were traded during mid-day trading, an increase of 333% from the previous session’s volume of 185,075 shares.The stock last traded at $28.25 and had previously closed at $26.85.

Several research analysts have recently issued reports on RGNX shares. Chardan Capital reiterated a “buy” rating and issued a $75.00 target price (up previously from $55.00) on shares of REGENXBIO in a research note on Tuesday, September 5th. Zacks Investment Research downgraded shares of REGENXBIO from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. BidaskClub upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Finally, Evercore ISI started coverage on shares of REGENXBIO in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 target price on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $37.00.

The company’s market cap is $872.76 million. The firm’s 50-day moving average price is $26.57 and its 200 day moving average price is $23.37.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.34. The company had revenue of $6.56 million for the quarter. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. Analysts expect that REGENXBIO Inc. will post ($2.87) EPS for the current year.

In other REGENXBIO news, CFO Vittal Vasista sold 3,100 shares of REGENXBIO stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $19.81, for a total transaction of $61,411.00. Following the completion of the sale, the chief financial officer now directly owns 108,423 shares in the company, valued at approximately $2,147,859.63. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Stephen Yoo sold 27,342 shares of REGENXBIO stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $25.00, for a total transaction of $683,550.00. Following the sale, the insider now owns 27,342 shares of the company’s stock, valued at $683,550. The disclosure for this sale can be found here. In the last three months, insiders have sold 116,140 shares of company stock worth $2,766,560. 17.00% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc lifted its stake in REGENXBIO by 41.4% during the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 2,011 shares during the period. Oxford Asset Management acquired a new stake in REGENXBIO during the 1st quarter valued at approximately $206,000. American International Group Inc. lifted its stake in REGENXBIO by 7.1% during the 1st quarter. American International Group Inc. now owns 12,468 shares of the biotechnology company’s stock valued at $241,000 after acquiring an additional 822 shares during the period. Voya Investment Management LLC acquired a new stake in REGENXBIO during the 2nd quarter valued at approximately $249,000. Finally, Asymmetry Capital Management L.P. lifted its stake in REGENXBIO by 12.2% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 1,508 shares during the period. Institutional investors and hedge funds own 73.23% of the company’s stock.

WARNING: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/17/regenxbio-inc-rgnx-sees-strong-trading-volume.html.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Receive News & Stock Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related stocks with our FREE daily email newsletter.